Physician profile
Scott Armond Larson
NPI 1467617050
$4,070.73
in general payments reported to CMS, 2019-2025
17 companies · $28.41 in 2025
The $28.41 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.05 · 2020: $28.14 · 2022: $843 · 2023: $1,459 · 2024: $1,689 · 2025: $28.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351 · Consulting Fee: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.87 |
| Consulting Fee | $825.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.54 | 2022-2024 | |
| Iterative Scopes, INC. | $825.00 | 2024 | Skout |
| Johnson & Johnson Health Care Systems INC. | $354.14 | 2023-2024 | Tremfya, Stelara, Darzalex |
| Medtronic, INC. | $342.10 | 2022-2024 | Nexpowder |
| Apollo Endosurgery US INC | $311.64 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Boston Scientific Corporation | $309.68 | 2019-2025 | Resolution Clip, Exalt Model D, Avvigo Guidance System |
| Conmed Corporation | $199.19 | 2023-2024 | Conmed Generators |
| Steris Corporation | $167.00 | 2023 | |
| Merck Sharp & Dohme LLC | $119.53 | 2023-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $119.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.80 | 2022-2024 | Xifaxan, Trulance |
| Ethicon US, LLC | $86.43 | 2023 | Linx Reflux Management System |
| Takeda Pharmaceuticals U.S.A., INC. | $72.40 | 2023-2024 | Entyvio, Gattex |
| Endogastric Solutions, INC | $50.03 | 2022 | |
| Alcresta Therapeutics, INC. | $46.07 | 2022-2023 | Relizorb |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $29.60 | 2022-2023 | Sucraid |
| Chiesi USA, INC. | $14.08 | 2024 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.